Zheng Quan Shi Bao Wang·2025-09-15 09:05Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, received approval from the National Medical Products Administration for new indications of two drugs, indicating a positive development in the company's product pipeline and potential market expansion [1] Group 1: Drug Approvals - The drug citric acid vorinostat capsules (brand name: Fuzhuoning) received approval for a new indication to be used in combination with aromatase inhibitors as initial endocrine therapy for adult patients with hormone receptor-positive and HER2-negative locally advanced or metastatic breast cancer [1] - The drug famotidine injection also received approval for its indication to treat upper gastrointestinal bleeding caused by peptic ulcers and other non-tumor-related conditions, excluding esophageal and gastric variceal bleeding [1]